University of Nebraska Medical Center

Chi Lin, MD, PhD, MS

Vice Chair of Research, UNMC Department of Radiation Oncology

Dr. Chi LIn

Chi Lin, MD, PhD, MS, is a professor and vice chair of research in the Department of Radiation Oncology of the UNMC College of Medicine. She provides clinical care as a radiation oncologist through UNMC's primary clinical partner, Nebraska Medicine. She is interested in GI and pediatric clinical and translational research. Her career plan is to be a successful clinician as well as a clinical investigator in the area of GI and pediatric cancer treatment.

Her long-term research goals:

  1. Use laboratory and clinical data to understand factors influencing treatment outcomes and to generate hypotheses for clinical trials.
  2. Design and develop clinical trials and to hasten the introduction of improved regimens for cancer therapy into everyday medical practice and patient care. 

Dr. Lin has a broad background in radiation oncology, with specific training and expertise in gastrointestinal cancer research and secondary data analysis.

  • Medical School: Medical Center of Fudan University, 1983
  • Graduate Education: Thomas Jefferson University, 1996
  • Internship: Hahnemann University Hospital, 1999
  • Residency: Radiation Oncology, Drexel University School of Medicine, 2003



Clinical trials to test the effects of radiation combining with novel radio-sensitizers or radio-protectors on cancers.

  1. 1) Pancreatic cancer SBRT with radiation sensitizers: Neoadjuvant chemoradiation therapy is an attractive approach to manage locally advanced pancreatic cancer. Not only can it allow patients with borderline resectable or unresectable disease to undergo resection, it may also reduce the rate of positive margins. Selecting non-progressors in a more refined manner may better avoid surgical morbidities. It has the major advantages of avoiding a protracted interval from diagnosis to surgery, along with increased patient convenience and enhanced cost-effectiveness. Our team was the first to test fractionated stereotactic body radiation therapy as part of neoadjuvant therapy for pancreatic cancer. We established SBRT dose and volume. On this platform, we tested radiosensitizers in efforts to improve the therapeutic ratio.
  2. 2) The effect of BMX-001 as a radioprotector: Radiation therapy with concurrent 5-fluorouracil and mitomycin-C (CRT) for patients with locally advanced anal squamous cell carcinoma results in long-term disease-free survival and sphincter preservation, but often with significant toxicity. RTOG trials showed 43-87% ≥ grade 3 acute toxicity. We are examining the effect of BMX-001, a scavenger of O2●- on decreasing CRT-associated toxicity in the lab and the clinic (phase I trial: NCT03386500). We are also examining the effect of combining BMX-001 with total neoadjuvant therapy on stage II/III rectal cancer patients on an NIH R01 grant sponsored phase III trial.
  3. 3) QOL of patients receiving radiation therapy.
Professional Memberships
  • American Society for Therapeutic Radiology and Oncology
  • American College of Radiation Oncology
  • American Society of Clinical Oncology
  • American College of Radiology